Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
暂无分享，去创建一个
C. Held | K. Alexander | P. Armstrong | F. Van de Werf | H. White | K. Mahaffey | L. Wallentin | Zhen Huang | R. Lopes | R. Harrington | P. Aylward | D. Moliterno | P. Tricoci | L. Armaganijan | J. Strony | E. Chen